OBJECTIVES: Risk factors of mortality in patients with haemodialysis (HD) have been identified in several studies, but few prognostic models have been developed with assessments of calibration and discrimination abilities. We used the database of the Assessment of Survival and Cardiovascular Events study to develop a prognostic model of mortality over 3-4 years. METHODS: Five factors (age, albumin, C-reactive protein, history of cardiovascular disease and diabetes) were selected from experience and forced into the regression equation. In a 67% random try-out sample of patients, no further factors amongst 24 candidates added significance (P < 0.01) to mortality outcome as assessed by Cox regression modelling, and individual probabilities of death were estimated in the try-out and test samples. Calibration was explored by calculating the prognostic index with regression coefficients from the try-out sample to patients in the 33% test sample. Discrimination was assessed by receiver operating characteristic (ROC) areas. RESULTS: The strongest prognostic factor in the try-out sample was age, with small differences between the other four factors. Calibration in the test sample was good when the calculated number of deaths was multiplied by a constant of 1.33. The five-factor model discriminated reasonably well between deceased and surviving patients in both the try-out and test samples with an ROC area of about 0.73. CONCLUSIONS: A model consisting of five factors can be used to estimate and stratify the probability of death for individuals The model is most useful for long-term prognosis in an HD population with survival prospects of more than 1 year.
RCT Entities:
OBJECTIVES: Risk factors of mortality in patients with haemodialysis (HD) have been identified in several studies, but few prognostic models have been developed with assessments of calibration and discrimination abilities. We used the database of the Assessment of Survival and Cardiovascular Events study to develop a prognostic model of mortality over 3-4 years. METHODS: Five factors (age, albumin, C-reactive protein, history of cardiovascular disease and diabetes) were selected from experience and forced into the regression equation. In a 67% random try-out sample of patients, no further factors amongst 24 candidates added significance (P < 0.01) to mortality outcome as assessed by Cox regression modelling, and individual probabilities of death were estimated in the try-out and test samples. Calibration was explored by calculating the prognostic index with regression coefficients from the try-out sample to patients in the 33% test sample. Discrimination was assessed by receiver operating characteristic (ROC) areas. RESULTS: The strongest prognostic factor in the try-out sample was age, with small differences between the other four factors. Calibration in the test sample was good when the calculated number of deaths was multiplied by a constant of 1.33. The five-factor model discriminated reasonably well between deceased and surviving patients in both the try-out and test samples with an ROC area of about 0.73. CONCLUSIONS: A model consisting of five factors can be used to estimate and stratify the probability of death for individuals The model is most useful for long-term prognosis in an HD population with survival prospects of more than 1 year.
Authors: A Rubio-Tapia; G Malamut; W H M Verbeek; R L J van Wanrooij; D A Leffler; S I Niveloni; C Arguelles-Grande; B D Lahr; A R Zinsmeister; J A Murray; C P Kelly; J C Bai; P H Green; S Daum; C J J Mulder; C Cellier Journal: Aliment Pharmacol Ther Date: 2016-08-03 Impact factor: 8.171
Authors: Brian Forzley; Lee Er; Helen H L Chiu; Ognjenka Djurdjev; Dan Martinusen; Rachel C Carson; Gaylene Hargrove; Adeera Levin; Mohamud Karim Journal: Palliat Med Date: 2017-07-21 Impact factor: 4.762
Authors: Chava L Ramspek; Pauline Wm Voskamp; Frans J van Ittersum; Raymond T Krediet; Friedo W Dekker; Merel van Diepen Journal: Clin Epidemiol Date: 2017-09-05 Impact factor: 4.790
Authors: Brian Forzley; Helen H L Chiu; Ognjenka Djurdjev; Rachel C Carson; Gaylene Hargrove; Dan Martinusen; Mohamud Karim Journal: Can J Kidney Health Dis Date: 2017-08-18
Authors: Chava L Ramspek; Wouter R Verberne; Marjolijn van Buren; Friedo W Dekker; Willem Jan W Bos; Merel van Diepen Journal: Clin Kidney J Date: 2020-03-17
Authors: Merel van Diepen; Marielle A Schroijen; Olaf M Dekkers; Joris I Rotmans; Raymond T Krediet; Elisabeth W Boeschoten; Friedo W Dekker Journal: PLoS One Date: 2014-03-04 Impact factor: 3.240
Authors: David de Gonzalo-Calvo; Pablo Martínez-Camblor; Christian Bär; Kevin Duarte; Nicolas Girerd; Bengt Fellström; Roland E Schmieder; Alan G Jardine; Ziad A Massy; Hallvard Holdaas; Patrick Rossignol; Faiez Zannad; Thomas Thum Journal: Theranostics Date: 2020-07-09 Impact factor: 11.556
Authors: Sophie Girerd; Nicolas Girerd; Luc Frimat; Hallvard Holdaas; Alan G Jardine; Roland E Schmieder; Bengt Fellström; Nicla Settembre; Sergei Malikov; Patrick Rossignol; Faiez Zannad Journal: Clin Kidney J Date: 2019-05-11
Authors: Madonna Salib; Sophie Girerd; Nicolas Girerd; Winfried März; Hubert Scharnagl; Ziad A Massy; Céline Leroy; Kévin Duarte; Hallvard Holdaas; Alan G Jardine; Roland E Schmieder; Bengt Fellström; Natalia López-Andrés; Patrick Rossignol; Faiez Zannad Journal: Clin Res Cardiol Date: 2021-06-25 Impact factor: 6.138